Gene therapy has shown exceptional promise and realization in curing genetic diseases. New vectors are in development to improve their efficacy, including biodistribution and transduction, while minimizing off-target or safety liabilities. Unbiased visualization of vector biodistribution and subsequent gene transduction in preclinical models are crucial in early-stage research; however, these critical studies are challenging to do using standard imaging modalities.

In this webinar, we introduce Cryo-Fluorescence Tomography (CFT) and Xerra™, a 3D imaging technology that allows whole-body detection and visualization of vector biodistribution and vector-mediated gene expression, in high resolution and with high sensitivity.

We present the results of a study conducted in collaboration with REGENXBIO, a leading gene therapy company. CFT with EMIT Imaging's Xerra system provided unbiased characterization of NAV® AAV7 expression in mice, enabling detection of protein expression in target and non-target organs, opening an avenue for treatment of new disease indications.

Matt Silva, PhD

CEO, EMIT Imaging

Matt Silva, PhD, is the CEO of EMIT Imaging, the leader in Cryo-Fluorescence Tomography (CFT) imaging. Previously, he served as CEO of Invicro, a global imaging CRO. Prior to Invicro, he led imaging biomarker groups at Vertex, Amgen, Millennium, and Takeda Pharmaceuticals. Matt holds a Ph.D. in Biomedical Engineering from Worcester Polytechnic Institute.

Hemi Dimant, PhD

Senior Director, Invicro

Hemi Dimant, PhD, is Senior Director, Scientific and Business Development at Invicro, where he designs preclinical research studies and provides scientific guidance. Dr. Dimant also serves as a Scientific Advisor for EMIT Imaging and leads Invicro's CFT contract research services. He holds a Ph.D. in Biotechnology from Tel Aviv University.

Jared B. Smith, PhD

Principal Scientist, REGENXBIO

Jared B. Smith, PhD, is Principal Scientist in Research and Early Development at REGENXBIO, developing gene therapy treatments for diseases of the central nervous system and advancing AAV technology for gene delivery. Dr. Smith received his Ph.D. in systems neuroscience from Penn State College.